Gynesonics, a Redwood City, CA-based women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, raised $43m in equity financing.
The round was co-led by new investor Endeavour Vision, with participation from existing investor Abingworth, HealthCrest, InterWest Partners, Advanced Technology Ventures (ATV), HBM Partners, Correlation Ventures and Hercules Technology Growth Capital.
The company intends to use the capital to fund its strategic clinical plan, which includes current and future trials in the U.S. and globally, key programs in operations and research and development, market adoption and to support global regulatory and reimbursement efforts for its technology platform, Sonata™.
Led by Christopher M. Owens, President and CEO, Gynesonics has developed the Sonata system, a minimally invasive, incision-free device that integrates radiofrequency energy to ablate fibroids under intrauterine sonography guidance, while preserving the uterus.
The system is CE Marked and approved for sale in the European Union while not available for sale in the United States.